Abstract
- There is a great need to swiftly develop vaccines and treatments against COVID-19 in the current pandemic. Yet, the time pressure and difficult circumstances to conduct clinical trials increases the risk of incomplete data sets, suboptimal study designs, and thus spurious results and reversals of decisions. - Open access to clinical trial and other patient-relevant data is necessary in order to provide transparency, and the possibility for validating clinical-trial analyses, and fully exploiting the information emerging from clinical trials. Thus, open access is critical in order to enable the successful and swift development of an effective intervention.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
